Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shares in Houston-based biopharmaceutical firm CytoGenix have seen a slight increase after the company obtained a commercial evaluation license from the US National Institutes of Health for an HIV vaccine.
Subscribe to our email newsletter
The National Institutes of Health (NIH) license covers a DNA plasmid developed by scientists from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC). It gives CytoGenix the right to conduct experiments using this proprietary DNA vaccine.
CytoGenix scientists will now conduct animal studies with a synthetic DNA vaccine derived from HIV gene sequences contained in the NIH plasmid.
“We have seen strong evidence of protein expression activity from our cell-free DNA in recent in vitro and in vivo experiments,” commented Dr Yin Chen, CytoGenix’ chief scientific officer. “Now we are poised to test against animal disease models such as HIV and influenza. We expect to see equal or greater levels of host immune response produced by our synthetic DNA vaccines than from the first generation plasmid DNA constructs.”